N,N'-di(o-hydroxybenzyl)-1,3-propanediamine-N,N'-diacetic acid | 63651-92-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N,N'-di(o-hydroxybenzyl)-1,3-propanediamine-N,N'-diacetic acid
• 英文别名: Glycine, N,N'-1,3-propanediylbis[N-[(2-hydroxyphenyl)methyl]-；2-[3-[carboxymethyl-[(2-hydroxyphenyl)methyl]amino]propyl-[(2-hydroxyphenyl)methyl]amino]acetic acid
• CAS: 63651-92-3
• 化学式: C₂₁H₂₆N₂O₆
• 分子量: 402.447
• InChiKey: KLVKTFLDHMZPHI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.4
• 重原子数：
  29
• 可旋转键数：
  12
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  122
• 氢给体数：
  4
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  N,N'di(o-hydroxybenzyl)-1,3-propanediamine-N,N'-diacetonitrile 以 concentrated HCl acid 、 水 为溶剂， 以34.6%的产率得到N,N'-di(o-hydroxybenzyl)-1,3-propanediamine-N,N'-diacetic acid
  参考文献：
  名称：

  N,N-di-(hydroxybenzyl)-trimethylene diaminediacetic acids

  摘要：

  一种新型的螯合剂具有以下结构式：##STR1##其中A. X.sub.1、X.sub.2、X.sub.3和X.sub.4中的每一个是从以下组成员中选择的：（i）氢；（ii）具有1-4个碳原子的烷基基团；（iii）-CN；（iv）-So.sub.3 M.sub.1；（v）-COOM.sub.1；（vi）-OM.sub.3；（vii）-NO.sub.2；（viii）-OH；和（ix）##STR2##其中R.sub.1和R.sub.2中的每一个是具有1-4个碳原子的烷基基团；B. M.sub.1、M.sub.2、M.sub.3和M.sub.4中的每一个是从以下组成员中选择的：（i）氢离子；（ii）碱金属离子；（iii）一半碱土金属离子；和（vi）具有以下结构式的铵离子：##STR3##其中R.sub.3、R.sub.4、R.sub.5和R.sub.6中的每一个是从以下组成员中选择的：（A）氢；（B）具有1-4个碳原子的烷基基团；和（C）具有1-4个碳原子的羟基烷基基团；C. Z是从以下组成员中选择的：（i）氢；和（ii）羟基。

  公开号：

  US04069249A1

文献信息

• STIMULI RESPONSIVE COMPOSITIONS FOR IRON CHELATION
  申请人：Xiong May Pang

  公开号：US20160184344A1

  公开（公告）日：2016-06-30

  The present technology provides new compositions comprising at least one cross-linked co-polymer. In some embodiments, the polyacrylamide co-polymer comprises water soluble subunits, cross-linking subunits, and iron chelating subunits. In other embodiments, the co-polymer comprises water soluble units, cross-linking subunits, and substituted subunits, which can be conjugated with iron-chelating agents. When these new particles are exposed to certain environments, such the presence of strong acids or oxidation agents, these particles are capable of breaking up so that the iron chelating agents can chelate iron or other metals from their environments. Methods to prepare these new compositions are also provided. These compositions or compositions comprising nanogels of the present technology may be used to treat metal overload conditions such as iron overload resulting from chronic transfusions.

  目前的技术提供了包含至少一种交联共聚物的新组合物。在某些实施例中，聚丙烯酰胺共聚物包括水溶性亚基、交联亚基和铁螯合亚基。在其他实施例中，共聚物包括水溶性单元、交联亚基和取代亚基，这些亚基可以与螯合铁的试剂结合。当这些新颗粒暴露在某些环境中，如强酸或氧化剂的存在时，这些颗粒能够分解，以便铁螯合试剂可以从它们的环境中螯合铁或其他金属。还提供了制备这些新组合物的方法。这些组合物或包含本技术的纳米凝胶的组合物可用于治疗金属过载症状，例如由于慢性输血导致的铁过载。
• Method and Topical Formulation for Treating Localized Edema
  申请人：Bhushan Rajiv

  公开号：US20100063152A1

  公开（公告）日：2010-03-11

  Methods and formulations are provided for the treatment of localized edema, particularly localized edema resulting from chronic venous insufficiency. A metal ion sequestrant is topically administered to a subject afflicted with localized edema in combination with a permeation enhancer selected from methylsulfonylmethane and a combination of methylsulfonylmethane and dimethylsulfoxide. Topically administrable formulations for use in the aforementioned method are also provided.
• US20140271825A1
  申请人：——

  公开号：US20140271825A1

  公开（公告）日：2014-09-18
• PHARMACEUTICAL FORMULATIONS OF CHELATING AGENTS AS A METAL REMOVAL TREATMENT SYSTEM
  申请人：ZONEONE PHARMA, INC.

  公开号：US20170128366A1

  公开（公告）日：2017-05-11

  The present invention provides liposomes loaded with chelating agents, pharmaceutical formulations including these liposomes and methods of making chelating agent liposomes. Because the chelating agents are loaded in the liposome with high efficiencies, the liposomes are of use in treatment of metal ion overload in subjects. The liposomes can include two or more different chelating agents of different structures and affinities for metal ions.
• METHODS AND TOPICAL FORMULATIONS FOR TREATING INFLAMMATION
  申请人：LIVIONEX, Inc.

  公开号：US20170209400A1

  公开（公告）日：2017-07-27

  Methods and formulations are provided for the treatment of localized edema, particularly localized edema resulting from chronic venous insufficiency. A metal ion sequestrant is topically administered to a subject afflicted with localized edema in combination with a permeation enhancer selected from methylsulfonylmethane and a combination of methylsulfonylmethane and dimethylsulfoxide. Topically administrable formulations for use in the aforementioned method are also provided.